Zobrazeno 1 - 10
of 1 013
pro vyhledávání: '"Charles M, Perou"'
Autor:
Natàlia Lorman-Carbó, Olga Martínez-Sáez, Aranzazu Fernandez-Martinez, Patricia Galván, Nuria Chic, Isabel Garcia-Fructuoso, Adela Rodríguez, Raquel Gómez-Bravo, Francesco Schettini, Paula Blasco, Oleguer Castillo, Blanca González-Farré, Barbara Adamo, Maria Vidal, Montserrat Muñoz, Charles M. Perou, Marcos Malumbres, Joaquín Gavilá, Tomás Pascual, Aleix Prat, Fara Brasó-Maristany
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract This study examines the biological effects of palbociclib and ribociclib in hormone receptor-positive breast cancer, pivotal to the HARMONIA prospective phase III clinical trial. We explore the downstream impacts of these CDK4/6 inhibitors,
Externí odkaz:
https://doaj.org/article/ea86ec3e16194f1f8bdd3ad02a335dd9
Autor:
Julia E. Altman, Amy L. Olex, Emily K. Zboril, Carson J. Walker, David C. Boyd, Rachel K. Myrick, Nicole S. Hairr, Jennifer E. Koblinski, Madhavi Puchalapalli, Bin Hu, Mikhail G. Dozmorov, X. Steven Chen, Yunshun Chen, Charles M. Perou, Brian D. Lehmann, Jane E. Visvader, J. Chuck Harrell
Publikováno v:
Clinical and Translational Medicine, Vol 14, Iss 10, Pp n/a-n/a (2024)
Abstract Background Breast cancer's complex transcriptional landscape requires an improved understanding of cellular diversity to identify effective treatments. The study of genetic variations among breast cancer subtypes at single‐cell resolution
Externí odkaz:
https://doaj.org/article/d0c391dda0a74b8395d749dfd6add293
Autor:
Natasha Vinod, Duhyeong Hwang, Sloane Christian Fussell, Tyler Cannon Owens, Olaoluwa Christopher Tofade, Thad S. Benefield, Sage Copling, Jacob D. Ramsey, Patrick D. Rädler, Hannah M. Atkins, Eric E. Livingston, J. Ashley Ezzell, Marina Sokolsky‐Papkov, Hong Yuan, Charles M. Perou, Alexander V. Kabanov
Publikováno v:
Bioengineering & Translational Medicine, Vol 9, Iss 5, Pp n/a-n/a (2024)
Abstract Triple‐negative breast cancer (TNBC) is notoriously difficult to treat due to the lack of targetable receptors and sometimes poor response to chemotherapy. The transforming growth factor beta (TGFβ) family of proteins and their receptors
Externí odkaz:
https://doaj.org/article/4d3e5270f8a24f30a1b80e2ded6ba463
Autor:
Alina M. Hamilton, Andrea Walens, Sarah C. Van Alsten, Linnea T. Olsson, Joseph Nsonwu-Farley, Xiaohua Gao, Erin L. Kirk, Charles M. Perou, Lisa A. Carey, Melissa A. Troester, Yara Abdou
Publikováno v:
Breast Cancer Research, Vol 26, Iss 1, Pp 1-11 (2024)
Abstract Purpose Survivin/BIRC5 is a proliferation marker that is associated with poor prognosis in breast cancer and an attractive therapeutic target. However, BIRC5 has not been well studied among racially diverse populations where aggressive breas
Externí odkaz:
https://doaj.org/article/27b60ce2e45d4cbb9f8f5a40b8cba4bf
Autor:
Tomás Pascual, Aranzazu Fernandez-Martinez, Yash Agrawal, Adam D. Pfefferle, Nuria Chic, Fara Brasó-Maristany, Blanca Gonzàlez-Farré, Laia Paré, Guillermo Villacampa, Cristina Saura, Cristina Hernando, Montserrat Muñoz, Patricia Galván, Xavier Gonzàlez-Farré, Mafalda Oliveira, Miguel Gil-Gil, Eva Ciruelos, Patricia Villagrasa, Joaquín Gavilá, Aleix Prat, Charles M. Perou
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-11 (2024)
Abstract In this study, we performed genomic analyses of cell cycle and tumor microenvironment changes during and after ribociclib and letrozole or chemotherapy in the CORALLEEN trial. 106 women with untreated PAM50-defined Luminal B early breast can
Externí odkaz:
https://doaj.org/article/3f189cf1ef8a4f74a950d11ff22079b9
Autor:
Benedetta Conte, Fara Brasó-Maristany, Adela Rodríguez Hernández, Tomás Pascual, Guillermo Villacampa, Francesco Schettini, Maria J. Vidal Losada, Elia Seguí, Laura Angelats, Isabel Garcia-Fructuoso, Raquel Gómez-Bravo, Natàlia Lorman-Carbó, Laia Paré, Mercedes Marín-Aguilera, Olga Martínez-Sáez, Barbara Adamo, Esther Sanfeliu, Beatrice Fratini, Claudette Falato, Núria Chic, Ana Vivancos, Patricia Villagrasa, Johan Staaf, Joel S. Parker, Charles M. Perou, Aleix Prat
Publikováno v:
EBioMedicine, Vol 102, Iss , Pp 105043- (2024)
Summary: Background: Early-stage triple-negative breast cancer (TNBC) displays clinical and biological diversity. From a biological standpoint, immune infiltration plays a crucial role in TNBC prognosis. Currently, there is a lack of genomic tools ai
Externí odkaz:
https://doaj.org/article/e280cec22ed2498189d321ebd159a946
Autor:
Mattia Rediti, Aranzazu Fernandez-Martinez, David Venet, Françoise Rothé, Katherine A. Hoadley, Joel S. Parker, Baljit Singh, Jordan D. Campbell, Karla V. Ballman, David W. Hillman, Eric P. Winer, Sarra El-Abed, Martine Piccart, Serena Di Cosimo, William Fraser Symmans, Ian E. Krop, Roberto Salgado, Sherene Loi, Lajos Pusztai, Charles M. Perou, Lisa A. Carey, Christos Sotiriou
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-18 (2023)
Abstract The identification of prognostic markers in patients receiving neoadjuvant therapy is crucial for treatment optimization in HER2-positive breast cancer, with the immune microenvironment being a key factor. Here, we investigate the complexity
Externí odkaz:
https://doaj.org/article/14a09996519f49368d11a06978543f0a
Autor:
Zhe Jiang, YoungJun Ju, Amjad Ali, Philip E. D. Chung, Patryk Skowron, Dong-Yu Wang, Mariusz Shrestha, Huiqin Li, Jeff C. Liu, Ioulia Vorobieva, Ronak Ghanbari-Azarnier, Ethel Mwewa, Marianne Koritzinsky, Yaacov Ben-David, James R. Woodgett, Charles M. Perou, Adam Dupuy, Gary D. Bader, Sean E. Egan, Michael D. Taylor, Eldad Zacksenhaus
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-22 (2023)
Abstract Metastatic breast-cancer is a major cause of death in women worldwide, yet the relationship between oncogenic drivers that promote metastatic versus primary cancer is still contentious. To elucidate this relationship in treatment-naive anima
Externí odkaz:
https://doaj.org/article/141fc3ada18346a59e6af3fd9ea5bbbb
Autor:
Frederick M. Howard, James Dolezal, Sara Kochanny, Galina Khramtsova, Jasmine Vickery, Andrew Srisuwananukorn, Anna Woodard, Nan Chen, Rita Nanda, Charles M. Perou, Olufunmilayo I. Olopade, Dezheng Huo, Alexander T. Pearson
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-6 (2023)
Abstract Gene expression-based recurrence assays are strongly recommended to guide the use of chemotherapy in hormone receptor-positive, HER2-negative breast cancer, but such testing is expensive, can contribute to delays in care, and may not be avai
Externí odkaz:
https://doaj.org/article/cc07ebb96cad409bab31f1a7e6989311
Autor:
Aleix Prat, Fara Brasó-Maristany, Olga Martínez-Sáez, Esther Sanfeliu, Youli Xia, Meritxell Bellet, Patricia Galván, Débora Martínez, Tomás Pascual, Mercedes Marín-Aguilera, Anna Rodríguez, Nuria Chic, Barbara Adamo, Laia Paré, Maria Vidal, Mireia Margelí, Ester Ballana, Marina Gómez-Rey, Mafalda Oliveira, Eudald Felip, Judit Matito, Rodrigo Sánchez-Bayona, Anna Suñol, Cristina Saura, Eva Ciruelos, Pablo Tolosa, Montserrat Muñoz, Blanca González-Farré, Patricia Villagrasa, Joel S. Parker, Charles M. Perou, Ana Vivancos
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-16 (2023)
Plasma ctDNA is a promising method to determine patient outcome in multiple cancer types. Here, the authors use shallow WGS to create machine learning signatures to identify tumor phenotypes and predict therapy response in patients with metastatic br
Externí odkaz:
https://doaj.org/article/3f12bbd8bddf4a1d9f66456aec50f23c